Argentine firm Andrómaco has closed a deal with Danish drugmaker Leo Pharma to bring Picato to Argentina The anti-actinic transparent gel will come under the firm’s prescription medicines business.
Argentine firm Andrómaco has closed a deal with Danish drugmaker Leo Pharma. The company, which belongs to the Roviralta family had already sealed deals with the European counterpart in the past, but is now reactivating the link in relation to one specific product.
The deal relates to the commercialization of Picato in Argentina. The drug is an anti-actinic transparent gel that will come under the firm’s prescription medicines business.
The product, based on ingenol mebutate will be the only one of its kind in the country, and is indicated for the treatment of actinic keratosis, crusty, scaly growths on the skin caused by excessive exposure to the sun. Ingenol belongs to a class off drugs called cytotoxic agents.
Picato comes in two formulations: one for the trunk and extremities and another for the face and scalp. It must be kept refrigerated at 2°c – 8°c.
